Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: Relation to the development of cardiovascular disease
- 1 July 1990
- journal article
- review article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 163 (1) , 392-395
- https://doi.org/10.1016/0002-9378(90)90589-y
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Risks and mechanisms of cardiovascular events in users of oral contraceptivesAmerican Journal of Obstetrics and Gynecology, 1988
- COAGULATION FACTORS AND THE PROGRESS OF CORONARY HEART DISEASEThe Lancet, 1987
- Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham StudyAmerican Heart Journal, 1987
- HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDYThe Lancet, 1986
- Fibrinogen as a Risk Factor for Stroke and Myocardial InfarctionNew England Journal of Medicine, 1984
- Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations.BMJ, 1980
- HÆMOSTATIC, LIPID, AND BLOOD-PRESSURE PROFILES OF WOMEN ON ORAL CONTRACEPTIVES CONTAINING 50 µg OR 30 µg ŒSTROGENThe Lancet, 1977
- Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of DrugsBMJ, 1970
- Investigation of Relation between Use of Oral Contraceptives and Thromboembolic Disease. A Further ReportBMJ, 1969
- Clotting Factors during Oral Contraception: Further ReportBMJ, 1966